[go: up one dir, main page]

BRPI0606391A2 - composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0606391A2
BRPI0606391A2 BRPI0606391-8A BRPI0606391A BRPI0606391A2 BR PI0606391 A2 BRPI0606391 A2 BR PI0606391A2 BR PI0606391 A BRPI0606391 A BR PI0606391A BR PI0606391 A2 BRPI0606391 A2 BR PI0606391A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
preparing
pharmaceutical formulation
Prior art date
Application number
BRPI0606391-8A
Other languages
English (en)
Inventor
Anders Broo
Patrick Holm
Robert Judkins
Lanna Li
Pernilla Sandberg
Marianne Swanson
Lars Weidolf
Kay Brickmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0606391A2 publication Critical patent/BRPI0606391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, PROCESSO PARA A PREPARAçãO DO MESMO, FORMULAçãO FARMACêUTICA, E, USO DE UM COMPOSTO OU DE UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO. A presente invenção diz respeito a certos novos compostos da fórmula (I) a processos para preparar tais compostos, à sua utilidade na modulação de receptores do hormónio nuclear do Receptor X hepático (LXR) <244> (NR1H3) e/ou <225> (NR1H2) e no tratamento e/ou prevenção de condições clínicas que incluem doenças cardiovasculares tais como aterosclerose; doenças inflamatórias, mal de Alzheimer, distúrbios lipídicos (dislipídemias) estejam associadas ou não com a resistência à insulina, diabete tipo 2 e outras manifestações da síndrome metabólica, a métodos para seu uso terapêutico e às composições farmacêuticas que os contenham.
BRPI0606391-8A 2005-01-10 2006-01-09 composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo BRPI0606391A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500055A SE0500055D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 3
PCT/SE2006/000029 WO2006073366A1 (en) 2005-01-10 2006-01-09 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0606391A2 true BRPI0606391A2 (pt) 2009-11-17

Family

ID=34132528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606391-8A BRPI0606391A2 (pt) 2005-01-10 2006-01-09 composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo

Country Status (19)

Country Link
US (2) US7723333B2 (pt)
EP (1) EP1838687A4 (pt)
JP (1) JP2008526844A (pt)
KR (1) KR20070094964A (pt)
CN (1) CN101137628A (pt)
AU (1) AU2006204164B2 (pt)
BR (1) BRPI0606391A2 (pt)
CA (1) CA2594404A1 (pt)
IL (1) IL184093A0 (pt)
MX (1) MX2007008405A (pt)
NO (1) NO20073250L (pt)
NZ (1) NZ556214A (pt)
RU (1) RU2415135C2 (pt)
SA (1) SA06270201B1 (pt)
SE (1) SE0500055D0 (pt)
TW (1) TW200804318A (pt)
UA (1) UA91992C2 (pt)
WO (1) WO2006073366A1 (pt)
ZA (1) ZA200705519B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526841A (ja) * 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
CA2785674A1 (en) * 2009-12-25 2011-06-30 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
AU2011299703A1 (en) 2010-09-07 2013-04-11 Snu R&Db Foundation Sesterterpene compounds and use thereof
AU2012214085B2 (en) 2011-02-11 2015-07-09 Nicoventures Trading Limited Inhaler component
CN110037999B (zh) 2012-08-13 2023-01-13 洛克菲勒大学 治疗和诊断黑素瘤
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
EP3317274A4 (en) 2015-06-30 2019-05-08 Eiger Group International, Inc. USE OF CHLOROQUIN AND CLEMIZOL COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND CANCER DISEASES
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
CN110105658B (zh) * 2019-04-04 2021-08-20 台州市黄岩聚丰机车有限公司 无卤阻燃聚丙烯电动自行车外饰件原材料
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428956A (en) * 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
IE53068B1 (en) * 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
US5411977A (en) * 1993-03-31 1995-05-02 The Dupont Merck Pharmaceutical Company Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and antithrombotic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
CN1304402A (zh) 1998-04-03 2001-07-18 三共株式会社 磺酰胺衍生物
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2001163786A (ja) 1999-09-30 2001-06-19 Sankyo Co Ltd スルホンアミド誘導体を含有する酵素阻害剤
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
CA2408747C (en) 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
MXPA03005140A (es) 2000-12-08 2004-10-15 Johnson & Johnson Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa.
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物
ES2310622T3 (es) * 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
GB0314302D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Novel compounds
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2008526841A (ja) * 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
WO2006073364A1 (en) * 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators

Also Published As

Publication number Publication date
CN101137628A (zh) 2008-03-05
US20100227847A1 (en) 2010-09-09
KR20070094964A (ko) 2007-09-27
US20090005353A1 (en) 2009-01-01
EP1838687A4 (en) 2010-11-17
WO2006073366A1 (en) 2006-07-13
EP1838687A1 (en) 2007-10-03
TW200804318A (en) 2008-01-16
SA06270201B1 (ar) 2009-12-16
JP2008526844A (ja) 2008-07-24
NZ556214A (en) 2010-07-30
AU2006204164B2 (en) 2009-11-05
CA2594404A1 (en) 2006-07-13
IL184093A0 (en) 2007-10-31
US7960380B2 (en) 2011-06-14
ZA200705519B (en) 2008-08-27
NO20073250L (no) 2007-07-19
MX2007008405A (es) 2007-09-21
SE0500055D0 (sv) 2005-01-10
US7723333B2 (en) 2010-05-25
UA91992C2 (ru) 2010-09-27
RU2415135C2 (ru) 2011-03-27
RU2007130151A (ru) 2009-02-20
AU2006204164A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
BRPI0606391A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
UY28407A1 (es) Agentes terapeuticos
UY28408A1 (es) Agentes terapeuticos
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
ECSP099409A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos
BR112014016648A8 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0410946A (pt) derivados de 2-(6-amino-piridin-3-il)-2-hidroxietilamina como agonistas de receptores adrenérgicos beta 2
BRPI0417323A (pt) indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
BR112014001642A2 (pt) fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas e uso das mesmas como medicamento
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
Zhang et al. Design, synthesis, and evaluation of a series of novel benzocyclobutene derivatives as general anesthetics
BRPI1007350B8 (pt) compostos espiro heterocíclicos bicíclicos
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BRPI0606388A2 (pt) composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
SE0500056D0 (sv) Therapeutic agents 4
BR112014016129A2 (pt) derivados de 1,3-difenilpropano, preparações e usos destes
SE0500058D0 (sv) Therapeutic agents 5

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.